Compare Quest Diagnostics Inc (DGX) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs GE Vernova Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while GE Vernova Inc trades at $1,075.01 (market cap $286.46B). The key difference: GE Vernova Inc is far larger — about 12.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | GEV | |
|---|---|---|
Market Cap | $22.80B | $286.46B |
Sector | Health | Technology |
52-Week High | $216.02 | $1.17K |
52-Week Low | $166.42 | $547.96 |
Enterprise Value | $28.82B | $279.09B |
Dividend Yield | 1.67% | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
GE Vernova (GEV) trades at $1,042.60, down 4.49% today, amid mixed technical signals but strong fundamental momentum. The stock shows bullish moving averages and oversold RSI conditions, while recent earnings beats and a 23.81% net income margin highlight robust profitability. Analyst consensus remains strongly bullish with a $1,240 price target, supported by the company's $11 billion investment in grid reliability and nuclear energy expansion.
Outlook: GEV's leadership in AI power infrastructure and nuclear technology positions it for long-term growth, though high valuation multiples (P/E 31.15) and execution risks on capital investments warrant caution. Near-term catalysts include Q2 2026 earnings on July 22, 2026, and dividend payments in July.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
